Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
ADVM 
Adverum Biotechnologies Inc (ADVM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/09/2025: ADVM (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $4.88
1 Year Target Price $4.88
| 5 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 203.49% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/09/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 96.26M USD | Price to earnings Ratio - | 1Y Target Price 4.88 |
Price to earnings Ratio - | 1Y Target Price 4.88 | ||
Volume (30-day avg) 7 | Beta 0.87 | 52 Weeks Range 1.78 - 5.75 | Updated Date 12/19/2025 |
52 Weeks Range 1.78 - 5.75 | Updated Date 12/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -8.57 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -76.9% | Return on Equity (TTM) -417.79% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 159137756 | Price to Sales(TTM) 94.37 |
Enterprise Value 159137756 | Price to Sales(TTM) 94.37 | ||
Enterprise Value to Revenue 158.41 | Enterprise Value to EBITDA 0.1 | Shares Outstanding 22077467 | Shares Floating 17756024 |
Shares Outstanding 22077467 | Shares Floating 17756024 | ||
Percent Insiders 13.21 | Percent Institutions 88.31 |
Upturn AI SWOT
Adverum Biotechnologies Inc
Company Overview
History and Background
Adverum Biotechnologies, Inc. was founded in 2007. It is a gene therapy company focused on developing and commercializing transformative therapies for unmet medical needs, particularly in ocular diseases. The company has undergone several strategic shifts and financing rounds to advance its pipeline.
Core Business Areas
- Gene Therapy Development: Adverum Biotechnologies focuses on the research, development, and potential commercialization of gene therapies for debilitating diseases. Their primary efforts are directed towards treating inherited retinal diseases and other serious ocular conditions.
Leadership and Structure
Adverum Biotechnologies is led by a management team with expertise in biotechnology and pharmaceutical development. The company operates as a publicly traded entity with a board of directors overseeing its strategic direction.
Top Products and Market Share
Key Offerings
- ADVM-022 (Ideficeptial): ADVM-022 is a gene therapy candidate designed for the treatment of neovascular age-related macular degeneration (AMD). It is delivered via a single intravitreal injection and aims to provide a sustained expression of a therapeutic protein. The market for AMD treatments is highly competitive, with key competitors including Regeneron (Eylea) and Roche (Lucentis), and emerging therapies from companies like Apellis Pharmaceuticals.
Market Dynamics
Industry Overview
The gene therapy market is a rapidly growing and innovative sector within the biopharmaceutical industry. It is characterized by significant scientific advancements, high research and development costs, and a focus on rare and debilitating diseases. Regulatory pathways are evolving, and the potential for one-time curative treatments drives significant investor interest.
Positioning
Adverum Biotechnologies is positioned as a gene therapy developer with a specific focus on ocular diseases. Its core advantage lies in its proprietary gene therapy platform, aiming to deliver durable therapeutic effects with a single administration. However, it operates in a highly competitive landscape with established players and other emerging gene therapy companies.
Total Addressable Market (TAM)
The TAM for treatments targeting conditions like neovascular AMD is substantial, running into billions of dollars globally. Adverum Biotechnologies aims to capture a portion of this market with its innovative gene therapy approach. Their positioning is to offer a potentially superior long-term treatment option compared to existing therapies.
Upturn SWOT Analysis
Strengths
- Proprietary gene therapy platform technology.
- Focus on significant unmet medical needs in ophthalmology.
- Potential for durable, single-administration treatment.
- Experienced management team in biotechnology.
Weaknesses
- Reliance on a single lead product candidate (ADVM-022) in late-stage development.
- High development costs and long timelines associated with gene therapies.
- Clinical trial risks and potential for unexpected adverse events.
- Limited commercialization experience.
Opportunities
- Growing demand for gene therapies and curative treatments.
- Expansion into other ocular or rare diseases with their platform.
- Potential partnerships or collaborations with larger pharmaceutical companies.
- Advancements in gene editing and delivery technologies.
Threats
- Failure of ADVM-022 in late-stage clinical trials.
- Intense competition from established pharmaceutical companies and other gene therapy developers.
- Stringent regulatory hurdles for gene therapy approvals.
- Pricing and reimbursement challenges for novel therapies.
- Potential for manufacturing or supply chain issues.
Competitors and Market Share
Key Competitors
- Regeneron Pharmaceuticals Inc. (REGN)
- Roche Holding AG (RHHBY)
- Apellis Pharmaceuticals Inc. (APLS)
- AbbVie Inc. (ABBV)
Competitive Landscape
Adverum Biotechnologies faces stiff competition in the ophthalmology market. Established players like Regeneron and Roche have significant market share with their approved therapies. Emerging companies like Apellis offer alternative treatment modalities. Adverum's advantage lies in its gene therapy approach, which could offer a more sustained and potentially curative treatment, but it must demonstrate superior efficacy and safety in clinical trials.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for Adverum Biotechnologies has been primarily characterized by progress in its gene therapy pipeline, including the advancement of ADVM-022 through clinical trial phases. Growth in terms of revenue is not applicable at this stage.
Future Projections: Future projections are heavily dependent on the successful clinical development and regulatory approval of ADVM-022. Analyst estimates would focus on potential market penetration, peak sales forecasts, and the timeline for achieving profitability post-commercialization.
Recent Initiatives: Recent initiatives likely involve ongoing clinical trial activities for ADVM-022, potential strategic partnerships, and efforts to optimize manufacturing and scale-up for potential commercial launch.
Summary
Adverum Biotechnologies is a clinical-stage gene therapy company with a promising candidate for ocular diseases. Its strength lies in its innovative platform and focus on unmet needs. However, it faces significant risks related to clinical trial success, competition, and regulatory hurdles. Continued progress in clinical development and securing adequate funding are crucial for its future.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Investor Presentations
- Industry Analyst Reports
- Financial News Outlets
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. Stock market investments involve risks, and past performance is not indicative of future results. Investors should conduct their own due diligence or consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Adverum Biotechnologies Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2014-07-31 | President, CEO & Director Dr. Laurent Fischer M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 155 | Website https://adverum.com |
Full time employees 155 | Website https://adverum.com | ||
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing BGTF-027 (AAV.7m8-L-opsin), a novel gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Ray Therapeutics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.